The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 866-870

  Chiu, Chih Chiang ^a,b,c   Chen, Chun Hsin ^a,d   Chen, Bo Yu ^c   Yu, Shu Han ^e   Lu, Mong Liang ^a,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Insulin resistance; Insulin secretion; Metabolic syndrome; Olanzapine; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CHOLESTEROL; HALOPERIDOL; LOW DENSITY LIPOPROTEIN; OLANZAPINE; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; BENZODIAZEPINE DERIVATIVE; GLUCOSE BLOOD LEVEL; INSULIN; NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; ACCOMODATION DISTURBANCE; ADULT; ARTICLE; BIPOLAR DISORDER; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; OPHTHALMOPLEGIA; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BODY WEIGHT; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; SECRETION (PROCESS); TIME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 77955049395     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.04.003     Document Type: Article

References (52)

1. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005, 54:862-871.
2. Almeras N., Despres J.P., Villeneuve J., Demers M.F., Roy M.A., Cadrin C., et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004, 65:557-564.
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC.
4. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004, 65:1335-1342.
5. Baptista T., Kin N.M., Beaulieu S., de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002, 35:205-219.
6. Barnett A.H., Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007, 21:357-373.
7. Bergman R.N., Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005, 66:504-514.
8. Chen C.H., Chiu C.C., Huang M.C., Wu T.H., Liu H.C., Lu M.L. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:925-931.
9. Chintoh A.F., Mann S.W., Lam L., Lam C., Cohn T.A., Fletcher P.J., et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008, 28:494-499.
10. Chintoh A.F., Mann S.W., Lam L., Giacca A., Fletcher P., Nobrega J., et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 2009, 108:127-133.
11. Chiu C.C., Chen K.P., Liu H.C., Lu M.L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006, 26:504-507.
12. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000, 26:903-912.
13. Duijnhoven E.M., Boots J.M., Christiaans M.H., Wolffenbuttel B.H., Van Hooff J.P. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001, 12:583-588.
14. Dwyer D.S., Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003, 75:255-260.
15. Dwyer D.S., Pinkofsky H.B., Liu Y., Bradley R.J. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23:69-80.
16. Elman I., Borsook D., Lukas S.E. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006, 31:2091-2120.
17. Engl J., Laimer M., Niederwanger A., Kranebitter M., Starzinger M., Pedrini M.T., et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005, 10:1089-1096.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
19. Goff D.C., Cather C., Evins A.E., Henderson D.C., Freudenreich O., Copeland P.M., et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005, 66:183-194.
20. Guy W. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology 1976, 217-222. National Institute of Mental Health, Rockville, MD, Revised (DHEW Publ. No. ADM 76-338).
21. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005, 19:16-27.
22. Hardy T.A., Marquez E., Kryzhanovskaya L., Taylor C.C., Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 2006, 26:405-408.
23. Heiskanen T., Niskanen L., Lyytikainen R., Saarinen P.I., Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003, 64:575-579.
24. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005, 62:19-28.
25. Henderson D.C., Copeland P.M., Borba C.P., Daley T.B., Nguyen D.D., Cagliero E., et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006, 67:789-797.
26. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32:289-297.
27. Howes O.D., Rifkin L. Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine. J Psychopharmacol 2004, 18:435-437.
28. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009, 120:274-280.
29. Hung C.F., Wu C.K., Lin P.Y. Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:523-527.
30. Hwang L.C., Bai C.H., Chen C.J. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006, 105:626-635.
31. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54:1552-1558.
32. Lambert M.T., Copeland L.A., Sampson N., Duffy S.A. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:919-923.
33. Lehtovirta M., Kaprio J., Groop L., Trombetta M., Bonadonna R.C. Heritability of model-derived parameters of beta cell secretion during intravenous and oral glucose tolerance tests: a study of twins. Diabetologia 2005, 48:1604-1613.
34. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987, 334:1-100.
35. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
36. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
37. Melkersson K., Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64:701-723.
38. Melkersson K., Khan A., Hilding A., Hulting A.L. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 2001, 11:327-332.
39. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
40. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl 4):8-13.
41. Newcomer J.W., Ratner R.E., Eriksson J.W., Emsley R., Meulien D., Miller F., et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009, 70:487-499.
42. Robinson K.A., Yacoub Wasef S.Z., Buse M.G. At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:93-98.
43. Sacher J., Mossaheb N., Spindelegger C., Klein N., Geiss-Granadia T., Sauermann R., et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008, 33:1633-1641.
44. Smith R.C., Lindenmayer J.P., Davis J.M., Kelly E., Viviano T.F., Cornwell J., et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009, 70:1501-1513.
45. Spoelstra J.A., Stolk R.P., Cohen D., Klungel O.H., Erkens J.A., Leufkens H.G., et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 2004, 65:674-678.
46. Sumiyoshi T., Roy A., Anil A.E., Jayathilake K., Ertugrul A., Meltzer H.Y. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol 2004, 24:345-348.
47. Tan C.E., Ma S., Wai D., Chew S.K., Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care 2004, 27:1182-1186.
48. Tighe S., Dinan T. An overview of the central control of weight regulation and the effect of antipsychotic medication. J Psychopharmacol 2005, 19:36-46.
49. Tura A., Sbrignadello S., Succurro E., Groop L., Sesti G., Pacini G. An empirical index of insulin sensitivity from short IVGTT: validation against the minimal model and glucose clamp indices in patients with different clinical characteristics. Diabetologia 2010, 53:144-152.
50. van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., et al. Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008, 69:472-479.
51. Vestri H.S., Maianu L., Moellering D.R., Garvey W.T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32:765-772.
52. Wu R.R., Zhao J.P., Liu Z.N., Zhai J.G., Guo X.F., Guo W.B., et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006, 186:572-578.